Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines

Drug Delivery and Translational Research

Volumn 4, Issue 3, 2014, Pages 233-245

  Wilkhu, Jitinder S ^a   McNeil, Sarah E ^a   Anderson, David E ^b   Perrie, Yvonne ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b Variation Biotechnologies   (United States)

Author keywords

Adjuvants; Cholesterol; Influenza; Niosomes; Non ionic vesicles; Vaccine delivery

Indexed keywords

ADJUVANT; BILE SALT; BILOSOME; CHOLESTEROL; DEOXYCHOLATE SODIUM; DRUG CARRIER; IMMUNOGLOBULIN G; INFLUENZA VACCINE; IODINE 125; MONOPALMITOYL GLYCEROL; NANOCARRIER; NIOSOME; NONIONIC SURFACTANT; RECOMBINANT PROTEIN; TRITIUM; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CONFOCAL LASER MICROSCOPY; DRUG DELIVERY SYSTEM; FEMALE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INTESTINE FLUID; INTESTINE LYMPHATIC TISSUE; ISOTOPE LABELING; KINETICS; LASER DIFFRACTION; MESENTERY; METHODOLOGY; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; STOMACH JUICE; VACCINATION; ZETA POTENTIAL;

EID: 84891587611     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0174-7     Document Type: Article

References (37)

1. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20-22): 2965-74. doi: 10. 1016/s0264-410x(00)00537-5.
2. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl): S45-53. doi: 10. 1038/nm1213.
3. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4-5): 394-407. doi: 10. 1016/j. addr. 2009. 11. 012.
4. Wilkhu J, McNeil SE, Kirby DJ, Perrie Y. Formulation design considerations for oral vaccines. Ther Deliv. 2011;2(9): 1141-64. doi: 10. 4155/tde. 11. 82.
5. Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006;34(5): 599-608. doi: 10. 1080/01926230600865531.
6. Webster DE, Gahan ME, Strugnell RA, Wesselingh SL. Advances in oral vaccine delivery options: what is on the horizon? Am J Drug Deliv. 2003;1(4): 227-40.
7. Mowat MA. Anatomical basis of tolerance and immunity to intestinal antigens. Nature. 2003;3: 331-41.
8. Mann JFS, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine. 2009;27(27): 3643-9. doi: 10. 1016/j. vaccine. 2009. 03. 040.
9. Kartoǧlu Ü. Temperature sensitivity of vaccines. Geneva: Switzerland; 2006.
10. Plotkin SA, Fletcher MA. Developments in immunization practices and strategies: implications for vaccine stability. Dev Biol Stand. 1996;87: 85-94.
11. Galazka AM, Milstien J, Zaffran M. Thermostability of vaccines: Global programme for Vaccines and Immunization. In: Organization WH, editor. Geneza, Switzerland 1998.
12. Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target. 2013;21(3): 291-9.
13. Henriksen-Lacey M, Bramwell V, Perrie Y. Radiolabelling of antigen and liposomes for vaccine: biodistribution studies. Pharmaceutics. 2010;2(2): 91-104.
14. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA: TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control Release. 2012;158(1): 72-7. doi: 10. 1016/j. jconrel. 2011. 10. 012.
15. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3): 413-7. doi: 10. 1016/j. ejpb. 2005. 03. 002.
16. Pedersen BL, Brondsted H, Lennernas H, Christensen FN, Mullertz A, Kristensen HG. Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharm Res. 2000;17(2): 183-9.
17. Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992;75(4): 570-5.
18. Singh M, O'Hagan D. The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv Drug Deliv Rev. 1998;34(2-3): 285-304. doi: 10. 1016/s0169-409x(98)00044-1.
19. Mane V, Muro S. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice. Int J Nanomedicine. 2012;7: 4223-37. doi: 10. 2147/IJN. S34105.
20. O'Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat. 1996;189(Pt 3): 477-82.
21. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Controlled Release. 1990;11(1-3): 205-14. doi: 10. 1016/0168-3659(90)90133-e.
22. van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials. 2001;22(7): 687-94. doi: 10. 1016/s0142-9612(00)00231-3.
23. Ebel JP. A method for quantifying particle absorption from the small intestine of the mouse. Pharm Res. 1990;7(8): 848-51. doi: 10. 1023/a: 1015964916486.
24. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 1996;14(17-18): 1677-85. doi: 10. 1016/s0264-410x(96)00149-1.
25. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in vivo experiments. J Pharm Pharmacol. 2008;60(1): 63-70. doi: 10. 1211/jpp. 60. 1. 0008.
26. Wolfensohn S, Lloyd M. Handbook of Laboratory Animal Management and Welfare, Third Edition. Blackwell; 2003.
27. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2): 148-58. doi: 10. 1038/nri1777.
28. Yeh P, Ellens H, Smith PL. Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. Adv Drug Deliv Rev. 1998;34(2-3): 123-33.
29. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine: Nanotechnol Biol Med. 2012;8(1): S5-20. doi: 10. 1016/j. nano. 2012. 07. 005.
30. Florence A. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14(3): 259-66. doi: 10. 1023/a: 1012029517394.
31. Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med. 1996;184(3): 1045-59. doi: 10. 1084/jem. 184. 3. 1045.
32. Plapied L, Duhem N, des Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci. 2011;16(Plapied L): 228-37. doi: 10. 1016/j. cocis. 2010. 12. 005.
33. Roda A, Mezzanotte L, Aldini R, Michelini E, Cevenini L. A new gastric-emptying mouse model based on in vivo non-invasive bioluminescence imaging. Neurogastroenterol Motil. 2010;22(10): 1117-e288. doi: 10. 1111/j. 1365-2982. 2010. 01535. x.
34. Marciani L, Faulks R, Wickham MS, Bush D, Pick B, Wright J, et al. Effect of intragastric acid stability of fat emulsions on gastric emptying, plasma lipid profile and postprandial satiety. Br J Nutr. 2009;101(6): 919-28. doi: 10. 1017/S0007114508039986S0007114508039986.
35. Holm R, Tonsberg H, Jorgensen EB, Abedinpour P, Farsad S, Mullertz A. Influence of bile on the absorption of halofantrine from lipid-based formulations. Eur J Pharm Biopharm. 2012;81(2): 281-7. doi: 10. 1016/j. ejpb. 2012. 03. 005S0939-6411(12)00080-X.
36. Holm R, Porter CJ, Edwards GA, Mullertz A, Kristensen HG, Charman WN. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci. 2003;20(1): 91-7.
37. Florence AT, Sakthivel T, Toth I. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J Control Release. 2000;65(1-2): 253-9. doi: 10. 1016/S0168-3659(99)00237-0.